A Phase 1/2, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Chronic Lymphocytic Leukemia.
Phase of Trial: Phase I/II
Latest Information Update: 31 Dec 2014
At a glance
- Drugs Dacetuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Seattle Genetics
- 12 Feb 2007 Status changed from recruiting to in progress.
- 31 Mar 2006 New trial record.